
Evaluating Breakthrough Technology: An FDA Perspective

David W. Feigal, Jr., M.D., M.P.H.,
Director, Center for Devices and
Radiological Health







Fast Track Products

Food Drug & Cosmetic Act

 Amended by the FDA Modernization Act of 1997 to include section 506: Fast Track Products

Two Qualifying Criteria:

- Intended to treat a serious or life- threatening condition
- Potential to address unmet medical needs for the condition



Treatment of Serious Conditions:

Examples

- a therapy directed at serious symptoms or serious manifestations of the condition;
- a diagnostic evaluated for the impact on a serious aspect of the condition;
- a preventive intended to prevent a serious aspect;
- a product which could ameliorate serious adverse effects of other treatments.



Address Unmet Medical Needs

Examples

- no existing therapy
- new therapy is better
- new therapy for patients intolerant or unresponsive to existing therapy
- new therapy is less toxic
- new therapy improves compliance (which is shown to improve effects on serious conditions)





Fast Track Products

Food Drug & Cosmetic Act

- Amended by the FDA Modernization Act of 1997 to include section 506: Fast Track Products
- Authorizes FDA to:
 - Facilitate Development
 - Expedite Review




Premarket


Postmarket




CDRH Vision - Total Product Life Cycle










CDRH Vision - Total Product Life Cycle



New Technologies

Issues

- Regulatory Path:
 - Drug?
 - Biological ?
 - Device ?
- Combination Products
 - Which Center Leads ?
- How to accelerate development ?



Acceleration: Options

Intensify

Telescope

Combine

Shorten

Simplify

Skip

Postpone



Acceleration: Options

Intensify

Telescope

Combine

Shorten

Simplify

Skip

Postpone

Lower Standards?

